{"id":9127,"date":"2018-12-06T11:15:00","date_gmt":"2018-12-06T10:15:00","guid":{"rendered":"https:\/\/irlab.se\/mfn_news\/natures-npj-parkinsons-disease-publicerar-klinisk-studie-med-irlabs-lakemedelskandidat-irl790\/"},"modified":"2018-12-06T11:15:00","modified_gmt":"2018-12-06T10:15:00","slug":"natures-npj-parkinsons-disease-publicerar-klinisk-studie-med-irlabs-lakemedelskandidat-irl790","status":"publish","type":"mfn_news","link":"https:\/\/irlab.se\/sv\/mfn_news\/natures-npj-parkinsons-disease-publicerar-klinisk-studie-med-irlabs-lakemedelskandidat-irl790\/","title":{"rendered":"Natures npj Parkinson\u2019s Disease publicerar klinisk studie med IRLAB:s l\u00e4kemedelskandidat IRL790"},"content":{"rendered":"

[mfn_before_post]<\/p>\n

IRLAB meddelade idag att en publikation baserad p\u00e5 den kliniska Fas Ib-studien med IRL790 i patienter med Parkinsons sjukdom och dyskinesier idag publicerats i den ansedda vetenskapliga tidskriften npj Parkinson\u2019s Disease utgiven av Nature.<\/strong><\/div>\n

IRL790 \u00e4r en av IRLAB:s ledande l\u00e4kemedelskandidater och utvecklas f\u00f6r behandling av dyskinesier och psykos vid Parkinsons sjukdom. Den kliniska Fas Ib-studien visar att IRL790 \u00e4r v\u00e4l tolererad och har en mycket god s\u00e4kerhetsprofil. Vidare visades den positiva effekten att dyskinesier minskade i gruppen behandlad med IRL790, men inte i placebogruppen. L\u00e4kemedelskandidaten genomg\u00e5r nu en klinisk Fas IIa-studie i en st\u00f6rre grupp patienter f\u00f6r vidare studier av den effekt som observerades i Fas Ib-studien.<\/span><\/p>\n

\u201dAtt v\u00e5r studie nu blir publicerad i tidskriften npj Parkinson\u2019s Disease<\/em> validerar v\u00e5r forskning och \u00e4r sj\u00e4lvklart en stor merit f\u00f6r IRLAB, v\u00e5ra samarbetspartners och studiens pr\u00f6vningsledare\u201d, sade Joakim Tedroff, medicinsk chef (CMO) p\u00e5 IRLAB.<\/span><\/p>\n

npj Parkinson\u2019s Disease <\/span><\/em>publiceras av Nature<\/em> och \u00e4r en internationell tidskrift som lyfter fram de viktigaste vetenskapliga framstegen inom forskning om Parkinsons sjukdom.<\/span><\/p>\n

Publikationen: Svenningsson, P. et al<\/em>. <\/span>Safety and tolerability of IRL790 in Parkinson\u2019s disease with levodopa-induced dyskinesia\u2014a phase 1b trial. npj Parkinson\u2019s Disease<\/em>. DOI-nummer 10.1038\/s41531-018-0071-3.<\/span><\/p>\n

L\u00e4nk till npj Parkinson\u2019s Diesease: www.nature.com\/npjparkd\/<\/a><\/p>\n

\n

F\u00f6r mer information<\/strong><\/p>\n

Nicholas Waters, VD\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0
Tel: +46 730 75 77 01\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 \u00a0 \u00a0\u00a0
E-post: nicholas.waters@irlab.se<\/a><\/p>\n

Joakim Tedroff, CMO\u00a0
Tel: +46 70\u00a0760 16 91
E-post: joakim.tedroff@irlab.se<\/a><\/p>\n<\/div>\n

\n

Om IRLAB<\/strong><\/p>\n

IRLAB \u00e4r ett forsknings- och utvecklingsbolag, listat p\u00e5 Nasdaq First North Premier som fokuserar p\u00e5 utveckling av nya l\u00e4kemedel f\u00f6r behandling av neurodegenerativa sjukdomar, i synnerhet Parkinsons sjukdom och demens.<\/p>\n

IRLAB har tv\u00e5 kliniska l\u00e4kemedelskandidater, IRL752 och IRL790, inriktade mot medicinska behov vid Parkinsons sjukdom, samt ytterligare projekt i preklinisk fas.<\/p>\n

IRLAB:s forskning syftar till att uppt\u00e4cka och utveckla nya l\u00e4kemedelskandidater f\u00f6r behandling av hj\u00e4rnans sjukdomar, d\u00e4r stora medicinska behov idag f\u00f6religger. Med hj\u00e4lp av den unika systembiologiska forskningsplattformen, ISP, uppt\u00e4cks dess nya behandlingsprinciper.<\/p>\n

IRLAB \u00e4r baserat i G\u00f6teborg. IRLAB:s verksamhet bedrivs huvudsakligen genom dotterbolaget Integrative Research Laboratories Sweden AB.<\/p>\n

F\u00f6r mer information, v\u00e4nligen bes\u00f6k\u00a0www.irlab.se<\/a>.<\/p>\n<\/div>\n

[mfn_after_post]<\/p>\n","protected":false},"excerpt":{"rendered":"

IRLAB meddelade idag att en publikation baserad p\u00e5 den kliniska Fas Ib-studien med IRL790 i patienter med Parkinsons sjukdom och dyskinesier idag publicerats i den ansedda vetenskapliga tidskriften npj Parkinson’s Disease utgiven av Nature.<\/p>\n","protected":false},"template":"","class_list":["post-9127","mfn_news","type-mfn_news","status-publish","hentry","mfn-news-tag-mfn-ci_sv","mfn-news-tag-mfn-type-ir_sv","mfn-news-tag-mfn_sv","mfn-news-tag-mfn-ci-other_sv","mfn-news-tag-mfn-lang-sv_sv"],"acf":[],"yoast_head":"\nNatures npj Parkinson\u2019s Disease publicerar klinisk studie med IRLAB:s l\u00e4kemedelskandidat IRL790 - IRLAB<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/irlab.se\/mfn_news\/natures-npj-parkinsons-disease-publicerar-klinisk-studie-med-irlabs-lakemedelskandidat-irl790\/\" \/>\n<meta property=\"og:locale\" content=\"sv_SE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Natures npj Parkinson\u2019s Disease publicerar klinisk studie med IRLAB:s l\u00e4kemedelskandidat IRL790 - IRLAB\" \/>\n<meta property=\"og:description\" content=\"IRLAB meddelade idag att en publikation baserad p\u00e5 den kliniska Fas Ib-studien med IRL790 i patienter med Parkinsons sjukdom och dyskinesier idag publicerats i den ansedda vetenskapliga tidskriften npj Parkinson's Disease utgiven av Nature.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/irlab.se\/mfn_news\/natures-npj-parkinsons-disease-publicerar-klinisk-studie-med-irlabs-lakemedelskandidat-irl790\/\" \/>\n<meta property=\"og:site_name\" content=\"IRLAB\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Ber\u00e4knad l\u00e4stid\" \/>\n\t<meta name=\"twitter:data1\" content=\"2 minuter\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/irlab.se\/mfn_news\/natures-npj-parkinsons-disease-publicerar-klinisk-studie-med-irlabs-lakemedelskandidat-irl790\/\",\"url\":\"https:\/\/irlab.se\/mfn_news\/natures-npj-parkinsons-disease-publicerar-klinisk-studie-med-irlabs-lakemedelskandidat-irl790\/\",\"name\":\"Natures npj Parkinson\u2019s Disease publicerar klinisk studie med IRLAB:s l\u00e4kemedelskandidat IRL790 - IRLAB\",\"isPartOf\":{\"@id\":\"https:\/\/irlab.se\/#website\"},\"datePublished\":\"2018-12-06T10:15:00+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/irlab.se\/mfn_news\/natures-npj-parkinsons-disease-publicerar-klinisk-studie-med-irlabs-lakemedelskandidat-irl790\/#breadcrumb\"},\"inLanguage\":\"sv-SE\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/irlab.se\/mfn_news\/natures-npj-parkinsons-disease-publicerar-klinisk-studie-med-irlabs-lakemedelskandidat-irl790\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/irlab.se\/mfn_news\/natures-npj-parkinsons-disease-publicerar-klinisk-studie-med-irlabs-lakemedelskandidat-irl790\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/irlab.se\/sv\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"MFN News Items\",\"item\":\"https:\/\/irlab.se\/sv\/pressmeddelanden\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Natures npj Parkinson\u2019s Disease publicerar klinisk studie med IRLAB:s l\u00e4kemedelskandidat IRL790\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/irlab.se\/#website\",\"url\":\"https:\/\/irlab.se\/\",\"name\":\"Irlab\",\"description\":\"Novel treatments for Parkinson's disease\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/irlab.se\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"sv-SE\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Natures npj Parkinson\u2019s Disease publicerar klinisk studie med IRLAB:s l\u00e4kemedelskandidat IRL790 - IRLAB","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/irlab.se\/mfn_news\/natures-npj-parkinsons-disease-publicerar-klinisk-studie-med-irlabs-lakemedelskandidat-irl790\/","og_locale":"sv_SE","og_type":"article","og_title":"Natures npj Parkinson\u2019s Disease publicerar klinisk studie med IRLAB:s l\u00e4kemedelskandidat IRL790 - IRLAB","og_description":"IRLAB meddelade idag att en publikation baserad p\u00e5 den kliniska Fas Ib-studien med IRL790 i patienter med Parkinsons sjukdom och dyskinesier idag publicerats i den ansedda vetenskapliga tidskriften npj Parkinson's Disease utgiven av Nature.","og_url":"https:\/\/irlab.se\/mfn_news\/natures-npj-parkinsons-disease-publicerar-klinisk-studie-med-irlabs-lakemedelskandidat-irl790\/","og_site_name":"IRLAB","twitter_card":"summary_large_image","twitter_misc":{"Ber\u00e4knad l\u00e4stid":"2 minuter"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/irlab.se\/mfn_news\/natures-npj-parkinsons-disease-publicerar-klinisk-studie-med-irlabs-lakemedelskandidat-irl790\/","url":"https:\/\/irlab.se\/mfn_news\/natures-npj-parkinsons-disease-publicerar-klinisk-studie-med-irlabs-lakemedelskandidat-irl790\/","name":"Natures npj Parkinson\u2019s Disease publicerar klinisk studie med IRLAB:s l\u00e4kemedelskandidat IRL790 - IRLAB","isPartOf":{"@id":"https:\/\/irlab.se\/#website"},"datePublished":"2018-12-06T10:15:00+00:00","breadcrumb":{"@id":"https:\/\/irlab.se\/mfn_news\/natures-npj-parkinsons-disease-publicerar-klinisk-studie-med-irlabs-lakemedelskandidat-irl790\/#breadcrumb"},"inLanguage":"sv-SE","potentialAction":[{"@type":"ReadAction","target":["https:\/\/irlab.se\/mfn_news\/natures-npj-parkinsons-disease-publicerar-klinisk-studie-med-irlabs-lakemedelskandidat-irl790\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/irlab.se\/mfn_news\/natures-npj-parkinsons-disease-publicerar-klinisk-studie-med-irlabs-lakemedelskandidat-irl790\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/irlab.se\/sv\/"},{"@type":"ListItem","position":2,"name":"MFN News Items","item":"https:\/\/irlab.se\/sv\/pressmeddelanden\/"},{"@type":"ListItem","position":3,"name":"Natures npj Parkinson\u2019s Disease publicerar klinisk studie med IRLAB:s l\u00e4kemedelskandidat IRL790"}]},{"@type":"WebSite","@id":"https:\/\/irlab.se\/#website","url":"https:\/\/irlab.se\/","name":"Irlab","description":"Novel treatments for Parkinson's disease","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/irlab.se\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"sv-SE"}]}},"_links":{"self":[{"href":"https:\/\/irlab.se\/sv\/wp-json\/wp\/v2\/mfn_news\/9127","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/irlab.se\/sv\/wp-json\/wp\/v2\/mfn_news"}],"about":[{"href":"https:\/\/irlab.se\/sv\/wp-json\/wp\/v2\/types\/mfn_news"}],"wp:attachment":[{"href":"https:\/\/irlab.se\/sv\/wp-json\/wp\/v2\/media?parent=9127"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}